Clinical trials: Triple Negative Breast Neoplasms, open to volunteers
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
The goal of this observational, retrospective, non interventional study is to learn about the efficacy of an Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer (TNBC).
- Trial name
- NEO-AgeTN (NCT07687446)
- Testing
- Non interventional study
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
- Trial name
- NCT06318897
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Triple Negative Breast Cancer (TNBC), Brain Metastasases
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.
- Trial name
- NCT06586866
- Testing
- JK-1201I
- Volunteers
- 25 people
- Sponsor
- JenKem Technology Co., Ltd.
TNBC - Triple-Negative Breast Cancer
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
The aim of this trial is to explore the real-world patient-reported health-related quality of life (HRQOL), functioning, symptoms and symptom tolerability of sacituzumab govitecan or chemotherapy of the physician's choice for…
- Trial name
- NCT06798506
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
TNBC - Triple-Negative Breast Cancer
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
This is an open, randomized, controlled, multicenter Phase III clinical study. Eligible subjects were randomly assigned 1:1 to albumin-paclitaxel plus carboplatin and carrilizumab with or without famitinib neoadjuvant therapy.
- Trial name
- BCTOP-T-N01 (NCT05999149)
- Testing
- Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 424 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid…
- Trial name
- NCT06249048
- Testing
- STX-001, Keytruda®
- Where
- 7 sites in United States, Australia
- Volunteers
- 108 people
- Sponsor
- Strand Therapeutics Inc.
TNBC - Triple-Negative Breast Cancer
Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)
The purpose of this study is to evaluate the treatment outcomes and safety of neoadjuvant therapy including pembrolizumab in real-world practice for patients with triple-negative breast cancer (TNBC) in a multi-center study in…
- Trial name
- NCT07828652
- Testing
- Medical record use research
- Volunteers
- 2,000 people
- Sponsor
- Yeon Hee Park
TNBC - Triple-Negative Breast Cancer
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with…
- Trial name
- NCT05862064
- Testing
- epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
TNBC, Triple Negative Breast Cancer
Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
This study is an observational study that retrospectively collects data of triple-negative breast cancer patients who received neoadjuvant therapy.
- Trial name
- NCT07523789
- Where
- China
- Volunteers
- 201 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, ER Positive Breast Cancer
Role of the Immune Environment in Response to Therapy in Breast Cancer
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers.
- Conditions
- Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05396612
- Testing
- Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer
The TASTY-steering Study
This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands.
- Conditions
- Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer, Stage II-IV Diffuse Large B Cell Lymphoma
- Trial name
- TASTY-steering (NCT07258563)
- Testing
- Taste steering
- Where
- 11 sites in Netherlands
- Volunteers
- 201 people
- Sponsor
- University Medical Center Groningen
Breast Cancer
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and…
- Trial name
- NCT04265872
- Testing
- Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Triple Negative Breast Cancer
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation.
- Trial name
- NCT03671044
- Testing
- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
- Where
- 4 sites in United States, India
- Volunteers
- 657 people
- Sponsor
- Jina Pharmaceuticals Inc.
Metastatic Urothelial Carcinoma, Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
- Conditions
- Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Trial name
- NCT07671092
- Testing
- RYZ211/212
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 40 people
- Sponsor
- RayzeBio, Inc.
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI).
- Conditions
- Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
- Trial name
- NCT07705438
- Testing
- [68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Breast Cancer, Advanced HR+/HER2- Breast Cancer
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer
The SATROPIN study is an international, multicenter, open-label, single-arm, phase II clinical trial to assess whether the use of prophylactic administration of atropine may prevent diarrhea in participants with unresectable…
- Conditions
- Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer
- Trial name
- SATROPIN (NCT07367178)
- Testing
- Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor)
- Volunteers
- 30 people
- Sponsor
- MedSIR
Fatigue Related to Cancer Treatment, Breast Cancer
Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.
- Trial name
- NuvastaticTM (NCT07669467)
- Testing
- Nuvastatic 300
- Where
- 6 sites in India
- Volunteers
- 250 people
- Sponsor
- Natureceuticals Sdn Bhd
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Triple Negative Breast Cancer (TNBC)
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic…
- Trial name
- NCT06189209
- Testing
- Tenalisib
- Where
- 9 sites in India
- Volunteers
- 40 people
- Sponsor
- Rhizen Pharmaceuticals SA